Resectable IIIA-N2 non-small-cell lung cancer (NSCLC): In search for the proper treatment.

Debora Brascia, Giulia De Iaco, Marcella Schiavone, Teodora Panza, Francesca Signore, Alessandro Geronimo, Doroty Sampietro, Michele Montrone, Domenico Galetta, Giuseppe Marulli

Research output: Contribution to journalReview articlepeer-review


Locally advanced non-small cell lung cancer accounts for one third of non-small cell lung cancer (NSCLC) at the time of initial diagnosis and presents with a wide range of clinical and pathological heterogeneity. To date, the combined multimodality approach involving both local and systemic control is the gold standard for these patients, since occult distant micrometastatic disease should always be suspected. With the rapid increase in treatment options, the need for an interdisciplinary discussion involving oncologists, surgeons, radiation oncologists and radiologists has become essential. Surgery should be recommended to patients with non-bulky, discrete, or single-level N2 involvement and be included in the multimodality treatment. Resectable stage IIIA patients have been the subject of a number of clinical trials and retrospective analysis, discussing the efficiency and survival benefits on patients treated with the available therapeutic approaches. However, most of them have some limitations due to their retrospective nature, lack of exact pretreatment staging, and the involvement of heterogeneous populations leading to the awareness that each patient should undergo a tailored therapy in light of the nature of his tumor, its extension and his performance status.

Original languageEnglish
Article number2050
Pages (from-to)1-31
Number of pages31
Issue number8
Publication statusPublished - Jul 25 2020


  • Adjuvant therapy
  • Locally advanced
  • Neoadjuvant therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Resectable IIIA-N2 non-small-cell lung cancer (NSCLC): In search for the proper treatment.'. Together they form a unique fingerprint.

Cite this